The study 's primary objective was to determine whether abacavir/lamivudine + atazanavir ( ABC/3TC + ATV ) was virologically non-inferior to tenofovir/emtricitabine + atazanavir/ritonavir ( TDF/FTC + ATV/r ) over 24 weeks in a population of virologically suppressed , HIV-1 infected patients .